Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
7.30
+0.15 (2.10%)
At close: Sep 26, 2025, 4:00 PM EDT
7.40
+0.10 (1.37%)
After-hours: Sep 26, 2025, 7:37 PM EDT
Astria Therapeutics Employees
Astria Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 19 or 32.20% compared to the previous year.
Employees
78
Change (1Y)
19
Growth (1Y)
32.20%
Revenue / Employee
n/a
Profits / Employee
-$1,498,987
Market Cap
411.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATXS News
- 10 days ago - Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology - Business Wire
- 22 days ago - Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 24 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 - Business Wire
- 4 weeks ago - Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference - Business Wire
- 6 weeks ago - Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
- 7 weeks ago - Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - Business Wire